Ezetimibe (Zetia) is a drug that lowers serum cholesterol by decreasing cholesterol absorption. It acts by inhibiting the Niemann-Pick C1-Like 1 protein (NPC1L1 protein) which is important in the cellular transport of cholesterol from the small intestine. LDL levels are significantly reduced, however clinical trials have largely failed to prove a mortality benefit. The IMPROVE-IT trial will report in mid-2013 and will be pivotal to answer this question.